David R. Proulx DVM, David M. Ruslander DVM, Richard K. Dodge MS, Marlene L. Hauck DVM, PHD, Laurel E. Williams DVM, Birgitte Horn BVSc, G. Sylvester Price DVM, PHD, Donald E. Thrall DVM, PHD First published: 19 May 2005...
BACKGROUND: We have used a schedule for soft x-ray therapy of epithelial malignancies that takes into account the clinically diagnosed tumor involution under treatment. OBJECTIVE: We sought to evaluate the effectiveness of this schedule in terms of cure rate and late...
This addendum to the code of practice for the determination of absorbed dose for x-rays below 300 kV has recently been approved by the IPEM and introduces three main changes: (i) Due to a lack of available data the original code recommended a value of unity for kch in the very-low-energy range (0.035–1.0 mm Al HVL). A single table of kch values, ranging from 1.01 to 1.07, applicable to both designated chamber types is now presented. (ii) For medium-energy x-rays (0.5–4 mm Cu HVL) methods are given to determine the absorbed dose to water either at 2 cm depth or at the surface of a phantom depending on clinical needs. Determination of the dose at the phantom surface is derived from an in-air measurement and by extending the low-energy range up to 4 mm Cu HVL. Relevant backscatter factors and ratios of mass energy absorption coefficients are given in the addendum. (iii) Relative dosimetry: although not normally forming part of a dosimetry code of practice a brief review of the current literature on this topic has been added as an appendix. This encompasses advice on techniques for measuring depth doses, applicator factors for small field sizes, dose fall off with increasing SSD and choice of appropriate phantom materials and ionization chambers.
R J Aukett, J E Burns, A G Greener, R M Harrison, C Moretti, A E Nahum and K E Rosser
Download Paper
With the significant increase in the average life-span in the industrial world, skin cancer has become a great health concern. There are various epidemiological, biological and molecular data suggesting that skin cancer is predominantly a disease of the elderly, since...
PURPOSE: We report on our experience in the treatment of T1 and T2 mycosis fungoides (MF) with total skin electron beam therapy (TSEBT), with respect to relapse-free rate, overall survival rate, and management of recurrence. METHODS AND MATERIALS: Between 1975 and...
PURPOSE: To determine the outcomes of patients with locally advanced basal cell and squamous cell carcinomas of the skin treated with radiotherapy. METHODS AND MATERIALS: A retrospective review of the outcomes of patients with basal cell and squamous cell carcinomas...
BACKGROUND: The histologic subtype of a basal cell carcinoma (BCC) may be an important factor for the success of a certain treatment modality. In the current article, the authors report recurrence rates among patients with BCC after superficial radiotherapy as well as...
Radiotherapy is an important modality in the treatment of non-melanoma skin cancers. While the majority of patients will be adequately treated without the need for radiotherapy, there are factors that may favour a recommendation for radiotherapy. The established roles...
Antony S.Mooref1 Department of Clinical Sciences, Head, Section of Oncology and Harrington Oncology Program, Tufts University School of Veterinary Medicine, 200 Westboro Road, North Grafton, MA, 01536, USA Abstract Radiation is becoming widely available to treat...
Contact Us